↓ Skip to main content

Dove Medical Press

Article Metrics

Estimating the health care burden of prescription opioid abuse in five European countries

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, September 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#4 of 329)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
9 news outlets
twitter
5 tweeters

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
34 Mendeley
Title
Estimating the health care burden of prescription opioid abuse in five European countries
Published in
ClinicoEconomics and Outcomes Research: CEOR, September 2015
DOI 10.2147/ceor.s85213
Pubmed ID
Authors

Amie Shei, Howard Birnbaum, Matthew Hirst, Caroline Enloe, William Dunlop, Noam Kirson

Abstract

Opioid abuse, including abuse of prescription opioids ("RxOs") and illicit substances like heroin, is a serious public health issue in Europe. Currently, there is limited data on the magnitude of RxO abuse in Europe, despite increasing public and scientific interest in the issue. The purpose of this study was to use the best-available data to derive comparable estimates of the health care burden of RxO abuse in France, Germany, Italy, Spain, and the United Kingdom (EU5). Published data on the prevalence of problem opioid use and the share of opioid abuse patients reporting misuse of non-heroin opioids were used to estimate the prevalence of RxO abuse in the EU5 countries. The costs of RxO abuse were calculated by applying published estimates of the incremental health care costs of opioid abuse to country-specific estimates of the costs of chronic pain conditions. These estimates were input into an economic model that quantified the health care burden of RxO abuse in each of the EU5 countries. Sensitivity analyses examined key assumptions. Based on best-available current data, prevalence estimates of RxO abuse ranged from 0.7 to 13.7 per 10,000 individuals across the EU5 countries. Estimates of the incremental health care costs of RxO abuse ranged from €900 to €2,551 per patient per year. The annual health care cost burden of RxO abuse ranged from €6,264 to €279,927 per 100,000 individuals across the EU5 countries. This study suggests that RxO abuse imposes a cost burden on health systems in the five largest European countries. The extent of RxO abuse in Europe should be monitored given the potential for change over time. Continued efforts should be made to collect reliable data on the prevalence and costs of RxO abuse in Europe to facilitate an accurate characterization of the extent of this potentially growing problem.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 3%
Unknown 33 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 21%
Other 6 18%
Student > Master 6 18%
Researcher 4 12%
Student > Bachelor 3 9%
Other 8 24%
Readers by discipline Count As %
Medicine and Dentistry 10 29%
Social Sciences 6 18%
Unspecified 5 15%
Agricultural and Biological Sciences 3 9%
Nursing and Health Professions 2 6%
Other 8 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 68. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2017.
All research outputs
#204,633
of 12,177,594 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#4
of 329 outputs
Outputs of similar age
#6,873
of 243,375 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#1
of 10 outputs
Altmetric has tracked 12,177,594 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 329 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,375 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them